SANTA
FE, N.M., July 23, 2024 /PRNewswire/ -- Mercury Bio (www.mercurybio.com), a New Mexico-based biotech company focused on
the development of a novel new drug-delivery platform, has
significantly accelerated its research timeline via a strategic
collaboration with four major scientific partners throughout the
Southwest.
Building upon a well-established relationship already in place
with Los Alamos National Laboratory (www.lanl.gov), Mercury Bio will now involve the National Center
for Genome Resources (www.ncgr.org), The University of New Mexico Health Sciences Center
(hsc.unm.edu), and the University of
Texas Medical Branch (www.utmb.edu) in controlled studies of
its yEV™ technology. Each laboratory brings technical expertise and
analytical capabilities to this multi-faceted biomolecular research
project designed to test and advance the use of yEVs, which are a
form of chimeric extracellular vesicle, to deliver assorted large
molecule drugs to a diversity of cell types.
Bruce McCormick, CEO of
Mercury Bio states, "Mercury Bio's unique technology, built on safe
yEV delivery vectors, is poised to usher in a new generation of RNA
therapeutic drugs to treat the cause of disease without the
devastating side effects so common in currently available
therapies." He continues, "This multi-partner collaboration
represents a major step forward in the development of our
platform—it will allow Mercury Bio
to rapidly demonstrate the safety and efficacy of delivery of
nucleic acids to targeted cells."
Mercury Bio CSO, Richard Sayre,
Ph.D., will present new data about the yEV™ platform in a talk
titled: yEVs — Enabling the High-Efficiency Introduction of
Diverse Cargos, Including mRNA, Functional Antibodies, and Enzymes,
to a Broad Range of Cell and Tissue Types, at the mRNA
Therapeutic Summit in Boston on
July 29, 2024.
About Mercury
Bio
Sparked by scientific breakthroughs in genomic
research, Mercury Bio has developed
a next-generation biomolecular drug delivery platform. The
technology prioritizes safety and efficacy while reducing side
effects by employing cell-specific targeting using a novel system
for drug encapsulation in natural vesicles. The result is an
advanced drug delivery system in a scalable, low-cost production
platform that will unlock the potential of RNA therapeutics and
small-molecule drugs.
Contact
Bruce McCormick
| Mercury Bio, CEO
380718@email4pr.com | +1 (800) 274–8533
www.mercurybio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/mercury-bio-announces-biomolecular-research-project-to-include-los-alamos-national-laboratory-the-national-center-for-genome-resources-the-university-of-new-mexico-and-the-university-of-texas-medical-branch-302203537.html
SOURCE Mercury Bio Inc.